Background Hypertension is a significant risk factor for cardiovascular disease, dementia and chronic kidney disease (CKD).

ADInstruments Lt educational platform provides pre designed laboratory exercises that incorporate physiological data acquisition, allowing students to perform ECG recordings while learning proper ...

HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application ...

HeartBeam (BEAT) announced its regulatory strategy following receipt of a Not Substantially Equivalent, or NSE, decision on the company’s 510(k) ...

HeartBeam is pursuing several parallel paths to address the FDA’s concerns, including a potential appeal process or resubmission of a 510 (k) application. The company noted that the appeal process ...

A 52-year-old man hospitalized with chest pain is found to have a slow heart rate and evidence of heart block. What does an ...

Austin, Texas, United States, November 20th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT) is on the verge of transforming how ...

Carotid artery disease restricts blood flow to the brain. Left undiagnosed, plaque buildup may lead to a stroke. Early detection may allow medication or lifestyle changes that lower the risk. A ...

Cambridge Heartwear Ltd., a trailblazer in medical device innovation and AI technology, is transforming the cardiovascular ...

In conclusion, HeartBeam’s earnings call reveals a company at a pivotal juncture, balancing significant progress with financial constraints. The overall sentiment is cautiously optimistic, with key ...

HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510 (k) ...

Reports Q3 2025 Results As FDA Review Nears Completion And Commercial Readiness Accelerates. HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward ...